7:33AM Alimera Sciences' ILUVIEN receives final published guidance from U.K.'s NICE; ILUVIEN is not cost effective for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies (ALIM) 1.74 : Co announced that the UK's National Institute for Health and Clinical Excellence (NICE) has published final guidance indicating that ILUVIEN is not cost effective for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This information is consistent with the final draft guidance issued on November 29, 2012 and does not take into account any potential for a patient access scheme (PAS). The NICE Appraisal Committee acknowledged the clinical effectiveness of ILUVIEN in the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies, but noted that cost-effectiveness thresholds for the product have not yet been met. Rather than appealing the Appraisal Committee's findings, Alimera has chosen to pursue a simple PAS for ILUVIEN that is intended to allow treatment decisions to be based on patient need, rather than cost. The PAS is currently under review by the Patient Access Schemes Liaison Unit (PASLU) at NICE and, if approved by the Department of Health, will be available to the Appraisal Committee for review and consideration. Alimera is pSivida's (PSDV) licensee for ILUVIEN for DME.
Market Data 
Markets 
AI
